Kelonia leads the way in advancing a fresh era of genetic medications through its innovative gene delivery platform. The company's sophisticated in vivo gene delivery technology, which is uncomplicated and advanced, employs a small number of powerful lentiviral vector-like particles to accurately and effectively transport genetic cargo to the specific target tissue in vivo, ensuring precise delivery every time. Initially concentrating on creating groundbreaking treatments for solid tumors and hematologic cancers, Kelonia is constructing a portfolio of genetic medications for various diseases with the ambitious aim of providing genetic medicines to all patients in need.